Personalized Cancer Vaccine Breakthrough
7:26–7:58 · 32s
Bancel details Moderna’s individualized cancer therapy, citing a 50 % five-year survival boost and predicting regulatory approval and patient access as early as next year.
7:26–7:58 · 32s
Bancel details Moderna’s individualized cancer therapy, citing a 50 % five-year survival boost and predicting regulatory approval and patient access as early as next year.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.